RB Loss Determines Selective Resistance and Novel Vulnerabilities in ER-Positive Breast Cancer Models

Using unbiased approaches, researchers found that PI3K and MTOR inhibitors emerged as potent inhibitors to delay proliferation of ER+ models harboring PIK3CA mutations.